Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
Blood|December 1, 2011
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaBruno Paiva, Norma C Gutiérrez, Laura Rosiñol, et al.
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsJuan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
Blood|August 2, 2008
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, et al.
Haematologica|March 7, 2008
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progressionMaría-Victoria Mateos, José M Hernández, Miguel T Hernández, et al.
Haematologica|July 10, 2012
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometryRoberto J Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, et al.
Blood|June 15, 2006
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyMaría-Victoria Mateos, José-M Hernández, Miguel-T Hernández, et al.
Blood|September 17, 2009
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, Maria-Belén Vidriales, Gema Mateo, et al.
The American Journal of Pathology|September 15, 2012
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trialsBruno Paiva, María-Belén Vídriales, María-Ángeles Montalbán, et al.
Blood Cancer Journal|April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma GroupAdrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Pageof 20